NCT03312517View on ClinicalTrials.gov

Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 15, 2018

Primary Completion Date

October 25, 2018

Study Completion Date

October 25, 2018

Conditions
Insomnia
Interventions
DRUG

Suvorexant 10 mg

Subject will receive suvorexant 10mg

DRUG

Suvorexant 20 mg

Subject will receive suvorexant 20mg

DRUG

Placebo oral capsule

Subject will receive placebo.

Trial Locations (1)

48377

Henry Ford Medical Center - Columbus, Novi

All Listed Sponsors
lead

Henry Ford Health System

OTHER

NCT03312517 - Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs | Biotech Hunter | Biotech Hunter